Acute Heart Failure Clinical Trial
— OFICAOfficial title:
French Observatory of Acute Heart Failure
NCT number | NCT01080937 |
Other study ID # | SFC-OFICA |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 2009 |
Est. completion date | February 2011 |
Verified date | September 2023 |
Source | French Cardiology Society |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
During the last decade, progress has been made in the management of heart failure. However, the changing characteristics of patients and practices in the "real world" and their impact on the prognosis of patients admitted for acute heart failure remain poorly studied. 2000 consecutive patients recruited in a single day in hospitals volunteered to participate in the cohort during a day dedicated.
Status | Completed |
Enrollment | 1818 |
Est. completion date | February 2011 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female age (e) over 18 years 2. Inpatient, whatever the mode of initial admission with acute heart failure (de novo heart failure or decompensation of chronic heart failure) regardless of severity, corresponding to one of the following clinical situations (clinical criteria in Appendix 1): - Pulmonary edema, hypertensive or not - congestive heart failure (pulmonary congestion and peripheral edema) - cardiogenic shock - Insufficient high output cardiac 3. Patients who agreed to participate in the study 4. Isolated right heart failure Exclusion Criteria: 1. expressed refusal to participate in the study 2. Hospitalization scheduled for review 3. Background surgery (immediate postoperative period) 4. Diagnosis of acute heart failure reversed in favor of an alternative diagnosis before discharge from hospital |
Country | Name | City | State |
---|---|---|---|
France | Lariboisiere Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
French Cardiology Society |
France,
Logeart D, Isnard R, Resche-Rigon M, Seronde MF, de Groote P, Jondeau G, Galinier M, Mulak G, Donal E, Delahaye F, Juilliere Y, Damy T, Jourdain P, Bauer F, Eicher JC, Neuder Y, Trochu JN; Heart Failure of the French Society of Cardiology. Current aspects — View Citation
Logeart D. [The OFICA study of acute heart failure]. Soins. 2013 Apr;(774):35. No abstract available. French. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival at 3 months | Analyze survival 3 months after the end of initial hospitalization | 3 months | |
Secondary | Hospital Methods | Compare methods of care based on clinical characteristics and hospital structures. | 3 months | |
Secondary | Patterns of admission | Analyze patterns of admission and discharge of patients, depending on their characteristics | 3 months | |
Secondary | Co-morbidities | Analyze the co-morbidities and their impact on care and survival | 3 months | |
Secondary | Drug treatments | Analyze the evolution of drug treatment between the output and monitoring to 3 months | 3 months | |
Secondary | Resources specific diagnostic | Analyze the use of resources specific diagnostic: measurement of BNP or NTproBNP, conducting echocardiogram, coronary angiography, Holter-ECG, Cardiac MRI, Cardiac CT | 3 months | |
Secondary | Therapeutic resources | Analyze the use of therapeutic resources based on specific clinical features: intensive care, ventilation, inotropes, ultrafiltration, introduction of beta-blockers, stimulation, implantable cardioverter defibrillator, circulatory support, graft | 3 months | |
Secondary | During of stay | Analyze the duration of stay according to clinical characteristics. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
Completed |
NCT02122640 -
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
Recruiting |
NCT05392764 -
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03717636 -
Early or Non-revoked in Hospital-day in Patients With Acute Heart Failure
|
N/A |